On the occasion of World Menopause Day , celebrated on October 18, L’Oréal Dermatological Beauty reaffirms its commitment to supporting women at all stages of life, including menopause, as a natural transition phase. In a society where stigmas still persist and the lack of adequate representation is questioned, L’Oréal continues to promote actions to raise awareness and offer solutions that allow women to live this stage with confidence and well-being.
The stages of menopause and perimenopause are phases that can bring about significant physical and emotional changes. Perimenopause is a transition in which estrogen and progesterone levels begin to decline, which can lead to visible changes in the skin such as increased sensitivity, loss of elasticity and a tendency toward dryness.
Leonor Prieto, Scientific Director of L’Oréal Dermatological Beauty, shares the recommendations that women should take into account at this stage for the care of their skin and their emotional well-being.
Leonor Prieto says that “menopause should be seen as a natural transition and an opportunity to renew the focus on personal care. At L’Oréal Dermatological Beauty, our goal is to offer effective, non-invasive, science-based solutions so that women feel comfortable and empowered at this stage.”
For this reason, L’Oréal Dermatological Beauty is joining in on this World Menopause Day to “promote a real and rigorous vision of this phase of life and provide women with the knowledge and support they need to take care of their skin and well-being in a comprehensive manner.”
L’Oréal’s dermatology division is on a mission to pioneer health and beauty, providing the world with sustainable and transformative dermatology solutions. Its four complementary brands respond to needs related to both pathologies and aesthetics: La Roche-Posay, CeraVe, Vichy and Skinceuticals. They all serve the purpose of supporting healthcare professionals to change people’s lives and increase access to skin health, for everyone, everywhere.
In recent years, LDB has achieved a record level of prescription share, with increased medical investment, reach and collaborations with health professionals, as well as advanced local scientific studies, doubling its turnover and gaining more than 6 points of market share, the company says.